clinical trial · NCT07686263
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb company·phase3·recruiting·n = 472
SchizophreniaXanomeline/Trospium ChloridePlacebo
brief summary
The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia
started
Aug 20, 2026
primary completion
Mar 3, 2029
completion
Mar 3, 2029
last updated
Sep 14, 2026
official title
A Phase 3 Double-blind, Placebo-controlled Randomized Withdrawal Maintenance Trial of KarXT Treatment in Participants With Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol